Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].

Liu ZY, Wei HS, Zhao HX, Liu YN, Zhao Y, Han N, Cheng J, Zhang FJ.

Zhonghua Yi Xue Za Zhi. 2007 Dec 11;87(46):3292-4. Chinese.

PMID:
18396628
2.

Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.

Liu J, Yue J, Wu S, Yan Y.

Arch Virol. 2007;152(10):1799-805. Epub 2007 Jul 6.

PMID:
17619115
3.

[Evolution of HIV-1 drug resistance in patients failing combination antiretroviral therapy].

Wang H, Zhang HM, Jiang Q, Peng QL, Tan Y, Li TS, Zhou BP.

Zhonghua Yi Xue Za Zhi. 2010 Mar 9;90(9):584-7. Chinese.

PMID:
20450778
4.

[Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].

Han XX, Zhang M, Cui WG, Liu BG, Wang Yn, Zhang ZN, Liu J, Geng WQ, Diao YY, Dai D, Jiang YJ, Shang H.

Zhonghua Yi Xue Za Zhi. 2005 Mar 23;85(11):760-4. Chinese.

PMID:
15949383
5.

Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.

Tolle M, Howard L, Kirk B, Gomila A, Schwarzwald H, Anabwani G.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug;11(4):260-8. doi: 10.1177/1545109711422273. Epub 2011 Oct 4.

PMID:
21972264
6.

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.

PMID:
19644384
7.

Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART).

Machado DM, Fernandes SC, Succi RC, Freire WS, Pannuti CS, Gouveia AB, Levi JE, Diaz RS.

Rev Inst Med Trop Sao Paulo. 2005 Jan-Feb;47(1):1-5. Epub 2005 Feb 23.

8.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

9.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group.

AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35.

PMID:
18195563
10.

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.

Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D; Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team.

AIDS. 2005 Sep 2;19(13):1385-91.

PMID:
16103769
11.

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID:
17693883
12.

HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.

Pham QD, Huynh TK, Luong TT, Tran T, Vu TX, Truong LX.

HIV Clin Trials. 2013 Jan-Feb;14(1):34-44. doi: 10.1410/hct1401-34.

PMID:
23372113
13.

Prevalence and evolution of drug resistance HIV-1 variants in Henan, China.

Li JY, Li HP, Li L, Li H, Wang Z, Yang K, Bao ZY, Zhuang DM, Liu SY, Liu YJ, Xing H, Shao YM.

Cell Res. 2005 Nov-Dec;15(11-12):843-9.

14.

High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.

Manasa J, Lessells RJ, Skingsley A, Naidu KK, Newell ML, McGrath N, de Oliveira T; Southern African Treatment and Resistance Network.

PLoS One. 2013 Aug 21;8(8):e72152. doi: 10.1371/journal.pone.0072152. eCollection 2013.

15.

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, Munsakul W, Prasithsirikul W, Sungkanuparph S, Bowonwattanuwong C, Klinbuayaem V, Petoumenos K, Hirschel B, Bhakeecheep S, Ruxrungtham K.

Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906.

PMID:
22024527
16.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
17.

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8.

PMID:
19779307
18.

Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1-infected children.

Almeida FJ, Berezin EN, Rodrigues R, Sáfadi MA, Arnoni MV, Oliveira C, Brígido LF.

J Pediatr (Rio J). 2009 Mar-Apr;85(2):104-9. doi: doi:10.2223/JPED.1877. English, Portuguese.

19.

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.

J Infect Dis. 2001 Jun 15;183(12):1732-8. Epub 2001 May 16.

PMID:
11372025
20.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503

Supplemental Content

Support Center